DNA抑制因子4作为急性淋巴细胞白血病临床复发前报告因子的可行性初探

本研究探讨以DNA抑制因子4作为急性淋巴细胞白血病（ALL）复发前报告因子的可行性。以骨髓持续完全缓解6—8个月的ALL患者为研究对象，应用甲基化特异性聚合酶链反应（MS—PCR）对经诱导缓解和巩固强化后持续完全缓解的32例ALL患者进行DNA抑制因子4启动子区甲基化状况分析，并随诊3个月以上。结果发现，32例完全缓解的ALL患者中20例（62．5％）DNA抑制因子4呈甲基化。12例DNA抑制因子4呈非甲基化的患者中只有1例3个月内复发，复发率8．33％，20例DNA抑制因子4呈甲基化状态的患者中10例3个月内复发，复发率50％。DNA抑制因子4甲基化与ALL患者初诊时是否具有高危因素并不完全相关。结论：DNA抑制因子4可作为ALL患者临床复发前的报告因子。

Preliminary Study on Id4 as A Reporter for ALL Patients before Relapse

This study was purposed to investigate the feasibility of inhibitor of DNA banding 4 (Id4) as a reporter for acute lymphoblastic leukemia (ALL) patients before their clinical relapse. Id4 promoter at methylation status was detected by MS-PCR in bone marrow samples from the ALL patients who had been in their complete remission (CR) for 6 to 8 months with follow-up period of at least three months. The results showed that Id4 methylation were found in 20 out of all 32 patients (62.5%). The remainder 12 patients were fourd Id4 unmethylated, 1 case out of whom relapsed within the next 3-month of follow-up (8.33%), while 10 out of 20 patients (50%) with Id4 methylation relapsed within the same follow-up period. Existence of high risk factors at de novo diagnosis didn't correlated with the Id4 methylation status. In conclusion, Id4 could be regard as a reporter for ALL patients before their relapse.